MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the year ending 2025-12-31.

Income Overview

Net Income
-$41,635K
EPS
-$3.71
Unit: Thousand (K) dollars

Income Statement
2025-12-31
Research and development
22,841
General and administrative
15,761
Total operating expenses
38,602
Operating loss
-38,602
Interest expense - royalty agreement
-5,818
Interest expense - convertible notes payable
0
Fair value adjustments on derivative liabilities - royalty agreement
-394
Fair value adjustments on convertible notes payable
0
Fair value adjustments on derivative liabilities - contingent value right liability
-218
Other income - german r&d tax credit receivable
0
Interest income, net
2,590
Other income (expense), net
727
Loss before income taxes
-41,715
Income tax benefit (expense)
0
Net loss
-41,715
Foreign currency translation gain
80
Comprehensive loss
-41,635
Basic EPS
-3.71
Diluted EPS
-3.71
Basic Average Shares
11,251,250
Diluted Average Shares
11,251,250
Unit: Thousand (K) dollars (except for numbers of shares and EPS).

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

DownloadDownload image
Comprehensive loss-$41,635K Foreign currencytranslation gain$80K Net loss-$41,715K Loss before incometaxes-$41,715K Interest income, net$2,590K Other income(expense), net$727K Operating loss-$38,602K Interest expense -royalty agreement-$5,818K Fair valueadjustments on derivative...-$394K Fair valueadjustments on derivative...-$218K Total operatingexpenses$38,602K Research and development$22,841K General andadministrative$15,761K

PALVELLA THERAPEUTICS, INC. (PVLA)

PALVELLA THERAPEUTICS, INC. (PVLA)